Shares of Faron Pharmaceuticals Oy (LON:FARN - Get Free Report) crossed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of GBX 216.86 ($2.98) and traded as low as GBX 185 ($2.54). Faron Pharmaceuticals Oy shares last traded at GBX 194.50 ($2.67), with a volume of 20,604 shares.
Faron Pharmaceuticals Oy Trading Up 5.1%
The company has a market cap of £261.12 million, a PE ratio of -5.20 and a beta of 0.36. The business's 50-day simple moving average is GBX 216.86 and its 200-day simple moving average is GBX 197.79. The company has a current ratio of 1.45, a quick ratio of 1.09 and a debt-to-equity ratio of 922.55.
Insider Activity
In other news, insider Markku Jalkanen sold 600,000 shares of the firm's stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of GBX 310 ($4.25), for a total transaction of £1,860,000 ($2,552,490.74). 31.82% of the stock is owned by insiders.
About Faron Pharmaceuticals Oy
(
Get Free Report)
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Faron Pharmaceuticals Oy, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Faron Pharmaceuticals Oy wasn't on the list.
While Faron Pharmaceuticals Oy currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
